Cellbunq Redefines Onboarding for Business Success Through Native Journeys
3.10.2023 13:23:00 CEST | Business Wire | Press Release
Cellbunq, a leading end-to-end verification platform provider specializing in business verification (KYB), proudly introduces groundbreaking solutions that streamline client onboarding, accelerate revenue generation, optimize operational costs, and establish unwavering trust with compliance officers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231003644027/en/
Native onboarding journeys available to global clients to further increase the conversion ratio of clients (Graphic: Business Wire)
Native Onboarding Journeys:
Cellbunq's unwavering commitment to exceptional onboarding experiences is exemplified by our native onboarding journeys. These journeys transcend mere translation of user steps; they offer an in-depth understanding of the documents accepted in specific regions, ensuring absolute clarity regarding documentation requirements.
Leveraging Cellbunq's comprehensive Know Your Business (KYB) solution, businesses can seamlessly onboard clients from 190+ countries within minutes. Our modular platform, capable of accommodating diverse onboarding journeys, consistently shortens time-to-revenue (TTR) and with the native onboarding journeys - significantly enhancing global conversion rates by allowing more clients to pass.
Automated Risk Classifications:
In our relentless pursuit of streamlined onboarding and informed decision-making, Cellbunq introduces automated risk classifications. This innovative feature empowers businesses to define criteria for categorizing clients as no-risk, low-risk, medium-risk and so on. Our system autonomously evaluates and assigns risk classifications, expediting onboarding while fortifying risk management practices.
By incorporating automated risk classifications, Cellbunq not only expedites the onboarding process but also equips businesses with a robust tool for data-driven decision-making. This advancement underscores Cellbunq's commitment to delivering secure, efficient, and compliant onboarding experiences.
Complete Crypto Compliance Solution:
Cellbunq has also unveiled a comprehensive crypto compliance solution, empowering crypto merchants to meet global regulatory standards, encompassing Know Your Business (KYB), Know Your Customer (KYC), Anti-money laundering (AML), crypto monitoring, and travel rule requirements. These enhancements solidify Cellbunq as a leader in efficient onboarding processes and compliance solutions, benefiting clients worldwide.
At Cellbunq, our mission is to enable clients to accelerate revenue, optimize costs, and become the trusted ally every compliance officer desires. With our native onboarding journeys, automated risk classifications, and comprehensive compliance solutions, we empower businesses to achieve these objectives seamlessly.
As the business landscape continues to evolve, Cellbunq remains dedicated to providing innovative solutions that drive success for our clients while supporting efficient onboarding, cost optimization, and excellence in compliance management.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231003644027/en/
Contact information
marketing@cellbunq.com
+46 76 0303 446
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom